CG Life is a different breed of agency, built for the unique challenges of bringing precision medicine to market. Biopharma companies advancing therapies for rare and hard-to-treat diseases face a commercialization gap. They need a partner who has been there before, fluent in complex science, deeply attuned to rare disease ecosystems, and capable of orchestrating every step of commercialization. CG Life is more than an agency—we are defining a new class of partner that understands the full journey. We’re the locals, with expertise in scientific translation and market shaping, omnichannel activation, and patient/HCP engagement, all underpinned by data, AI, and deep domain expertise in rare and complex therapies. Let’s get to extraordinary. Together. Expert capabilities in: Brand Strategy Public Relations Social Media Creative Scientific Communications Omnichannel Strategy & Enablement Media Planning Analytics & Insights
External link for CG Life
657 W Lake Street
Chicago, IL 60661, US
4920 Carroll Canyon Road
Suite 100
San Diego, CA 92121, US
We’re encouraged to see the reinstatement of the Rare Pediatric Disease Priority Review Voucher Program, a key initiative that has helped accelerate development across dozens of rare diseases. Too many #RareDisease patients still have no approved treatment, and this is a very important step forward for research and development.
BIO's statement on the passage of the bipartisan appropriations package. https://lnkd.in/e6jfyMPe
For the past few years, the J.P. Morgan Healthcare Conference has been buzzing with uncertainty. As geopolitics and global health crises have reshaped the healthcare landscape, leaders have been forced to adapt in real time. This year, things felt different. Instead of waiting for clarity, the industry showed signs of something more durable: a willingness to execute within constraints. In Med Ad News/ PharmaLive, our CEO David Ormesher reflects on why this year’s conference marked a meaningful inflection point. From pricing and access moving upstream to AI shedding its hype phase in favor of impact strategies, #JPM2026 revealed an industry committed to moving forward in imperfect conditions. Read Beyond the Stage: Why JPM 2026 Was More Important Than It Looked: https://lnkd.in/ez6ddU7r
Rare Disease Month is a time to recognize the people at the heart of the #RareDisease community. The patients navigating uncertainty with resilience. The caregivers showing up every day with unwavering strength and compassion. The advocacy organizations building connection and momentum. And the healthcare professionals and researchers pushing science forward, often against long odds. Progress in rare disease doesn’t happen overnight. It’s built through persistence, partnership, and a shared belief that every patient counts, no matter how rare. #RareDiseaseMonth #PatientsFirst #Caregivers #Advocacy #HealthcareProfessionals
We heard a lot at #JPM2026, so we asked attendees one simple question: What’s your word for 2026? From “AI” (a lot of it) to “excitement," the answers gave us a look into what’s top of mind across the industry. Whether you attended JPM or watched from afar, what's your word of the year? Comment below!
CG Life *is* growing, but we’ve been made aware of fraudulent messages from individuals falsely claiming to recruit on our behalf. We’re excited to connect with talented, curious, and collaborative people. If something feels off, it probably is. Be sure to check the email domain and trust your instincts. Interested in joining our team the right way? Explore our open roles on our website here: https://lnkd.in/gybP7zt
A quick note for job seekers: We’ve been made aware that some candidates are being contacted by individuals falsely claiming to represent CG Life and requesting interviews for open roles posted on our website. Please know: -All recruiting outreach and communication from CG Life will only come from an email address ending in [at]cglife.com -We will never ask candidates to pay fees or share financial information at any point in the hiring process If you’re contacted by someone using a different email domain or asking for money or sensitive details, please consider it fraudulent.
After 40+ years in pharma advertising, one lesson still stands out: people do their best work when their thinking is respected. In MM+M, Jay Carter, EVP, Business Development at CG Life, reflects on how that belief has shaped his leadership, and why it continues to matter for the quality of work delivered to clients. Read the full article in MM+M: https://lnkd.in/eUE-YzJW #Leadership #AgencyLife #HealthcareMarketing #LeadWithHeart
CG Life reposted this
Day 3 at #JPM26 felt like the moment when optimism met pragmatism. After Day 1’s reset and Day 2’s pricing reality check, today’s conversations were more about what it actually takes to execute. Pricing agreements may have restored some predictability, but executives were candid that they came with trade-offs. What stood out was how openly CEOs talked about compromise. Sanofi and BMS framed their “most-favored nation” deals not as wins or losses, but as difficult negotiations that preserved long-term investment theses while enabling lower prices through new direct-to-patient access. Policy constraints are no longer being negotiated away, they are being baked into strategy and new business models. At the same time, manufacturing, speed, and competitiveness dominated the subtext. Legend Biotech reported operating profit for its one-dose CAR-T therapy, underscoring how investments in manufacturing capacity and site readiness can be as critical to access as reimbursement. AbbVie, meanwhile, demonstrating its legendary operational discipline, outlined plans for ten head-to-head trials, asserting its confidence. But venture investors continued to push, questioning why the U.S. system can’t move with the urgency it proved possible during the pandemic, especially as China accelerates. Bob Nelsen of ARCH Venture Partners offered one of the most blunt quotes of the week on STAT's podcast: "We know we can go faster... I don’t blame China for being competitive. I blame the U.S. for not stepping up and competing." Day 3 reinforced a deeper shift underway. Yes, execution is about accelerating life science innovations into product pipelines, but it must include navigating trade-offs faster than competitors, across regulation, pricing, and global competition. We're dealing with reality as it is, not as we wish it to be. #cglife
CG Life reposted this
Day 2 at JPM put pricing and access squarely on the front burner. Across pharma presentations, leaders weren’t arguing that affordability pressures have eased; instead, they were signaling that success now depends on how well companies operationalize in support of their core focus. Both Lilly and Novo Nordisk were notably cautious on forecasts, emphasizing longer-term market sizing, payer dynamics, and new access pathways over headline growth. Elsewhere, loss of exclusivity loomed large, with Bayer, Merck, and others framing patent cliffs less as cliffs than as long, manageable slopes, as long as pipelines and partnerships deliver. Generics and biosimilars players sounded newly confident, positioning access as a growth engine. What struck me most was how often access strategy was positioned alongside clinical strategy: Medicare Part D assumptions, cash/direct-pay channels, regional manufacturing, and payer engagement no longer play just supporting roles. Day 2 reinforced the notion that innovation alone isn’t enough; the winners will be those who can navigate price, access, and focus, all at the same time.
CG Life reposted this
JPM week started before sunrise with our second annual Sweat Equity 5K. At 6 a.m. in Union Square, about 100 attendees gathered. We weren’t there to debate policy or markets, but to run together through San Francisco before the city was awake. It was a small but telling moment: energy was up, conversations were friendly, and the outlook was less about bracing for bad news than getting back into our stride. That shift carried into the conference… After several years when “uncertainty” was the code word of the conference, Day 1 felt like a reset—from navigating volatility to getting back to growth. With U.S. drug pricing deals providing a measure of clarity (including AbbVie’s announcement on Monday), CEOs were able to get back to the business of defining their clinical development progress, especially in rare and hard-to-treat diseases, where new modalities are critical. What stood out was how often AI came up not as a promise, but as a practical force multiplier. One example came from Apellis Pharmaceuticals, which is developing AI tools to translate standard OCT scans into functional vision maps, helping patients and families see, quite literally, the real-world visual impact of geographic atrophy. The annual keynote lunch interview with Jamie Dimon added a big picture perspective to the day. His candid reflections on business, politics, and healthcare reinforced a sentiment that echoed across conversations: leaders can't wait for perfect clarity. We must plan and move forward. #JPM26 #CGLife
We’re excited to hit the ground running in 2026 at next week’s 44th Annual J.P. Morgan Healthcare Conference! CG Life’s presence at the industry’s premier event will include CEO David Ormesher, SVP of Public Relations Karen Sharma, and Managing Director of our Strategic Communications Group Erik Clausen, supporting our clients and connecting with leaders across biotech, pharma and life science organizations. If you’re attending #JPM26, we would love to connect: https://lnkd.in/eRkFJxYA